Long survival in B-CLL correlates with surface IgM kappa phenotype

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• B-cell chronic lymphocytic leukaemia (B-CLL) is a common lymphoid malignancy.
• Early diagnosis and staging are crucial for patient management and prognosis.
• Understanding prognostic markers can improve treatment strategies.

Purpose of the Study:

• To investigate the prognostic significance of surface immunoglobulin (Ig) expression in B-CLL.
• To correlate surface Ig phenotypes with clinical presentation and disease progression.
• To assess the impact of IgM kappa expression on patient survival.

Main Methods:

• Retrospective analysis of 200 B-CLL patients over 13 years.
• Clinical data collection including diagnosis, stage, lymphocyte count, and treatment requirement.
• Analysis of surface Ig expression (IgM kappa vs. others) on leukaemic cells.
• Statistical analysis of correlations between Ig phenotype and clinical parameters/survival.

Main Results:

• Most B-CLL diagnoses (72.2%) were incidental, with 70.1% at stage A.
• Patients with IgM kappa expressed leukaemic cells were significantly more likely to be stage A.
• IgM kappa expression correlated with lower lymphocyte counts, less progressive disease, and reduced treatment need.
• Patients with IgM kappa demonstrated significantly longer actuarial survival, even when stratified by stage or age.

Conclusions:

• Surface IgM kappa expression is a significant favorable prognostic marker in B-CLL.
• This marker can predict earlier stage at diagnosis and slower disease progression.
• IgM kappa expression is associated with improved long-term survival in B-CLL patients.